NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Prof. Dimitrios Karussis, Principal Investigator of the Company’s clinical trials at Hadassah Medical Center in Jerusalem, presented some of his preliminary findings from the ongoing Phase IIa dose-escalating trial evaluating the company’s NurOwn™ technology, at the 24th International Symposium on ALS/MND last week in Milan, Italy.
Help employers find you! Check out all the jobs and post your resume.
